Vesilute (Lys-Glu-Asp, KED) is a synthetic tripeptide (MW ~390.4 g/mol) from the Khavinson bioregulatory peptide family, developed as a vascular-specific bioregulator. It is proposed to restore endothelial function, reduce atherosclerotic changes, and improve vascular elasticity in aging. Published primarily in Russian literature.
Category: Cardiovascular / Anti-Aging. Evidence rating: D (animal/preclinical only).
Clinical status: Russian clinical studies in elderly patients with vascular disease. Not validated in Western trials.
Vesilute is proposed to modulate gene expression in vascular endothelial and smooth muscle cells, restoring production of nitric oxide synthase, elastin, and other structural/functional proteins that decline with vascular aging. It may reduce endothelial dysfunction, improve vascular compliance,…
Safety considerations: Reported as well-tolerated; No serious adverse events in published literature; Simple tripeptide with expected low toxicity.
Reviewed by the PeptideAtlas Editorial Team.
| Amino-acid sequence | Lys-Glu-Asp (KED) |
|---|---|
| Molecular formula | C14H24N4O8 |
| Molecular weight | ~390.4 g/mol |
| Half-life | ~15-30 minutes |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | Research peptide. Not FDA-approved. |
Related peptides: Cardiogen.
Vesilute has limited evidence from Russian studies. It is not validated by Western clinical standards. For cardiovascular disease, use established evidence-based treatments under physician guidance.
Vesilute is a Khavinson bioregulator tripeptide researched for vascular tissue support and blood vessel wall function, particularly in age-related cardiovascular changes.
VESILUTE has been studied for: Vascular tissue support, Blood vessel function, Endothelial health, Age-related vascular support. Khavinson bioregulator; vascular/blood vessel focus.
Short peptide bioregulator that may modulate gene expression in vascular endothelial cells, supporting vessel wall integrity and smooth muscle function.